Y-mAbs Therapeutics Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Y-mAbs Therapeutics does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
-0.4%
Rückkaufsrendite
Gesamte Aktionärsrendite | -0.4% |
Zukünftige Dividendenrendite | 0% |
Wachstum der Dividende | n/a |
Nächster Dividendenzahlungstermin | n/a |
Ex-Dividendendatum | n/a |
Dividende pro Aktie | n/a |
Ausschüttungsquote | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 12Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?
May 12Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if YMAB's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if YMAB's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
Y-mAbs Therapeutics Dividendenrendite im Vergleich zum Markt |
---|
Segment | Dividendenrendite |
---|---|
Unternehmen (YMAB) | n/a |
Untere 25 % des Marktes (US) | 1.5% |
Markt Top 25 % (US) | 4.5% |
Branchendurchschnitt (Biotechs) | 2.2% |
Analystenprognose (YMAB) (bis zu 3 Jahre) | 0% |
Bemerkenswerte Dividende: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate YMAB's payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as YMAB has not reported any payouts.